Working towards further advances in immuno-oncology
Immuno-oncology has emerged as a promising approach to cancer treatment, taking advantage of our own immune system to fight the disease. Recent progress in understanding the intricacies of the immune system has directed the development of new therapies and potential strategies to further impact the efficacy of current treatments.
Fluidigm is committed to providing the right tools and services to support advances in immuno-oncology research, including cell profiling and biomarker identification. Our optimized, flexible and efficient assays are designed to meet the rigorous demands of translational and clinical research programs.
Immuno-Oncology with Imaging Mass Cytometry
Immuno-Oncology with Microfluidics
Unless explicitly and expressly stated otherwise, all Fluidigm products are provided for Research Use Only, not for use in diagnostic procedures. For more information see www.fluidigm.com/legal/notices